US investor backs SIMPLE antibody discovery firm in €27.5m fundraising
This article was originally published in Scrip
Executive Summary
arGEN-X, a small European biotech company focused on the discovery and development of human monoclonal antibodies from its SIMPLE antibody discovery platform, has closed a €27.5 million ($37 million) series B fundraising round, which was oversubscribed. The fundraising was co-led by OrbiMed Advisors of the US and Seventure Partners of France.